Friday, 5 February 2016

Global Pain Therapeutics, Inc. Market Business Survey Report Product Pipeline Review 2015 - Acute Market Reports

'PAIN THERAPEUTICS, INC. - Product Pipeline Review - 2015', provides an overview of the PAIN THERAPEUTICS, INC.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of PAIN THERAPEUTICS, INC.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

View Full Reporthttp://www.acutemarketreports.com/report/pain-therapeutics-inc-product-pipeline-review-2015

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of PAIN THERAPEUTICS, INC. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of PAIN THERAPEUTICS, INC.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the PAIN THERAPEUTICS, INC.'s pipeline products

Reasons to buy

- Evaluate PAIN THERAPEUTICS, INC.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of PAIN THERAPEUTICS, INC. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the PAIN THERAPEUTICS, INC.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of PAIN THERAPEUTICS, INC. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of PAIN THERAPEUTICS, INC.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of PAIN THERAPEUTICS, INC. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

About Us:
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends. Our database consists of 200,000+ market research reports with detailed & minute market research.
Acute Market Reports
Office No 101, 1st Floor,
Aditi Mall, Baner,
Pune, MH, 411045
India
Toll Free(US/CANADA): +1-855-455-8662

Market overview - Global Biotest AG Market Report Product Pipeline Review 2015 - By Acute Market Reports

'BIOTEST AG - Product Pipeline Review - 2015', provides an overview of the BIOTEST AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of BIOTEST AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

View Full Reporthttp://www.acutemarketreports.com/report/biotest-ag-product-pipeline-review-2015

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of BIOTEST AG including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of BIOTEST AG's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the BIOTEST AG's pipeline products

Reasons to buy

- Evaluate BIOTEST AG's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of BIOTEST AG in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the BIOTEST AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of BIOTEST AG and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of BIOTEST AG
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of BIOTEST AG and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

About Us:
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends. Our database consists of 200,000+ market research reports with detailed & minute market research.
Acute Market Reports
Office No 101, 1st Floor,
Aditi Mall, Baner,
Pune, MH, 411045
India
Toll Free(US/CANADA): +1-855-455-8662

New Study On Global Jiangsu Hengrui Medicine Co., Ltd. Market Report Product Pipeline Review 2015 - Acute Market Reports

'JIANGSU HENGRUI MEDICINE CO., LTD. - Product Pipeline Review - 2015', provides an overview of the JIANGSU HENGRUI MEDICINE CO., LTD.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of JIANGSU HENGRUI MEDICINE CO., LTD.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

View Full Reporthttp://www.acutemarketreports.com/report/jiangsu-hengrui-medicine-co-ltd-product-pipeline-review-2015

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of JIANGSU HENGRUI MEDICINE CO., LTD. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of JIANGSU HENGRUI MEDICINE CO., LTD.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the JIANGSU HENGRUI MEDICINE CO., LTD.'s pipeline products

Reasons to buy

- Evaluate JIANGSU HENGRUI MEDICINE CO., LTD.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of JIANGSU HENGRUI MEDICINE CO., LTD. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the JIANGSU HENGRUI MEDICINE CO., LTD.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of JIANGSU HENGRUI MEDICINE CO., LTD. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of JIANGSU HENGRUI MEDICINE CO., LTD.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of JIANGSU HENGRUI MEDICINE CO., LTD. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

About Us:
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends. Our database consists of 200,000+ market research reports with detailed & minute market research.
Acute Market Reports
Office No 101, 1st Floor,
Aditi Mall, Baner,
Pune, MH, 411045
India
Toll Free(US/CANADA): +1-855-455-8662

Recent Release On Global Arena Pharmaceuticals, Inc. Market Report Product Pipeline Review 2015 - Acute Market Reports

'ARENA PHARMACEUTICALS, INC. - Product Pipeline Review - 2015', provides an overview of the ARENA PHARMACEUTICALS, INC.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ARENA PHARMACEUTICALS, INC.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

View Full Reporthttp://www.acutemarketreports.com/report/arena-pharmaceuticals-inc-product-pipeline-review-2015

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of ARENA PHARMACEUTICALS, INC. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of ARENA PHARMACEUTICALS, INC.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the ARENA PHARMACEUTICALS, INC.'s pipeline products

Reasons to buy

- Evaluate ARENA PHARMACEUTICALS, INC.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of ARENA PHARMACEUTICALS, INC. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the ARENA PHARMACEUTICALS, INC.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of ARENA PHARMACEUTICALS, INC. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of ARENA PHARMACEUTICALS, INC.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of ARENA PHARMACEUTICALS, INC. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

About Us:
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends. Our database consists of 200,000+ market research reports with detailed & minute market research.
Acute Market Reports
Office No 101, 1st Floor,
Aditi Mall, Baner,
Pune, MH, 411045
India
Toll Free(US/CANADA): +1-855-455-8662

Wednesday, 27 January 2016

Global Genital Warts (Condylomata Acuminata) Market Segmentation and Forecast Product Pipeline Review 2016 - Acute Market Reports

'Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2015', provides an overview of the Genital Warts (Condylomata Acuminata)'s therapeutic pipeline.

This report provides comprehensive information on the current therapeutic developmental pipeline of GENITAL WARTS (CONDYLOMATA ACUMINATA)'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

View Full Reporthttp://www.acutemarketreports.com/report/genital-warts-condylomata-acuminata-pipeline-review-h1-2015

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of GENITAL WARTS (CONDYLOMATA ACUMINATA) including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of GENITAL WARTS (CONDYLOMATA ACUMINATA)'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the GENITAL WARTS (CONDYLOMATA ACUMINATA)'s pipeline products

Reasons to buy

- Evaluate GENITAL WARTS (CONDYLOMATA ACUMINATA)'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of GENITAL WARTS (CONDYLOMATA ACUMINATA) in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the GENITAL WARTS (CONDYLOMATA ACUMINATA)'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of GENITAL WARTS (CONDYLOMATA ACUMINATA) and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of GENITAL WARTS (CONDYLOMATA ACUMINATA)
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of GENITAL WARTS (CONDYLOMATA ACUMINATA) and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

About Us:
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends. Our database consists of 200,000+ market research reports with detailed & minute market research.
Acute Market Reports
Office No 101, 1st Floor,
Aditi Mall, Baner,
Pune, MH, 411045
India
Toll Free(US/CANADA): +1-855-455-8662

Global Corneal Neovascularization Market Edition and Outlook Report Product Pipeline Review 2016 - Acute Market Reports

'Corneal Neovascularization - Pipeline Review, H1 2015', provides an overview of the Corneal Neovascularization's therapeutic pipeline.

This report provides comprehensive information on the current therapeutic developmental pipeline of CORNEAL NEOVASCULARIZATION's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

View Full Reporthttp://www.acutemarketreports.com/report/corneal-neovascularization-pipeline-review-h1-2015

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of CORNEAL NEOVASCULARIZATION including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of CORNEAL NEOVASCULARIZATION's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the CORNEAL NEOVASCULARIZATION's pipeline products

Reasons to buy

- Evaluate CORNEAL NEOVASCULARIZATION's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of CORNEAL NEOVASCULARIZATION in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the CORNEAL NEOVASCULARIZATION's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of CORNEAL NEOVASCULARIZATION and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of CORNEAL NEOVASCULARIZATION
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of CORNEAL NEOVASCULARIZATION and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

About Us:
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends. Our database consists of 200,000+ market research reports with detailed & minute market research.
Acute Market Reports
Office No 101, 1st Floor,
Aditi Mall, Baner,
Pune, MH, 411045
India
Toll Free(US/CANADA): +1-855-455-8662

Global Dysmenorrhea Market Size, Share, Trend, Growth, Analysis and Forecast Report Product Pipeline Review 2016 - Acute Market Reports

'Dysmenorrhea - Pipeline Review, H1 2015', provides an overview of the Dysmenorrhea's therapeutic pipeline.
This report provides comprehensive information on the current therapeutic developmental pipeline of DYSMENORRHEA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Download Full Report With TOChttp://www.acutemarketreports.com/request-free-sample/36805
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides brief overview of DYSMENORRHEA including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of DYSMENORRHEA's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the DYSMENORRHEA's pipeline products
View all Reports of this Category @: http://www.acutemarketreports.com/category/healthcare-market
Reasons to buy
- Evaluate DYSMENORRHEA's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of DYSMENORRHEA in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the DYSMENORRHEA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of DYSMENORRHEA and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of DYSMENORRHEA
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of DYSMENORRHEA and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
About Us:
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends. Our database consists of 200,000+ market research reports with detailed & minute market research.
Acute Market Reports
Office No 101, 1st Floor,
Aditi Mall, Baner,
Pune, MH, 411045
India
Toll Free(US/CANADA): +1-855-455-8662

Thursday, 21 January 2016

Global H. Lundbeck A/S Market Business Survey Report Product Pipeline Review 2016 - Acute Market Reports

'H. LUNDBECK A/S - Product Pipeline Review - 2015', provides an overview of the H. LUNDBECK A/S's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of H. LUNDBECK A/S's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

View Full Reporthttp://www.acutemarketreports.com/report/h-lundbeck-as-product-pipeline-review-2015

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of H. LUNDBECK A/S including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of H. LUNDBECK A/S's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the H. LUNDBECK A/S's pipeline products

Reasons to buy

- Evaluate H. LUNDBECK A/S's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of H. LUNDBECK A/S in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the H. LUNDBECK A/S's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of H. LUNDBECK A/S and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of H. LUNDBECK A/S
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of H. LUNDBECK A/S and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

About Us:
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends. Our database consists of 200,000+ market research reports with detailed & minute market research.
Acute Market Reports
Office No 101, 1st Floor,
Aditi Mall, Baner,
Pune, MH, 411045
India
Toll Free(US/CANADA): +1-855-455-8662

Thursday, 7 January 2016

Can-Fite BioPharma Ltd. - Product Pipeline Review Market Overview Report 2015 - Acute Market Reports

'CAN-FITE BIOPHARMA LTD. - Product Pipeline Review - 2015', provides an overview of the CAN-FITE BIOPHARMA LTD.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CAN-FITE BIOPHARMA LTD.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

View Full Report:
http://www.acutemarketreports.com/report/can-fite-biopharma-ltd-product-pipeline-review-2015

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.


Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of CAN-FITE BIOPHARMA LTD. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of CAN-FITE BIOPHARMA LTD.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the CAN-FITE BIOPHARMA LTD.'s pipeline products


Reasons to buy

- Evaluate CAN-FITE BIOPHARMA LTD.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of CAN-FITE BIOPHARMA LTD. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the CAN-FITE BIOPHARMA LTD.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of CAN-FITE BIOPHARMA LTD. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of CAN-FITE BIOPHARMA LTD.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of CAN-FITE BIOPHARMA LTD. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

About Us:
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends. Our database consists of 200,000+ market research reports with detailed & minute market research.
Acute Market Reports
Office No 101, 1st Floor,
Aditi Mall, Baner,
Pune, MH, 411045
India
Toll Free(US/CANADA): +1-855-455-8662
Website: http://www.acutemarketreports.com/

Karus Therapeutics Limited - Product Pipeline Review Market Edition and Outlook Report 2015 - Acute Market Reports

'KARUS THERAPEUTICS LIMITED - Product Pipeline Review - 2015', provides an overview of the KARUS THERAPEUTICS LIMITED's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of KARUS THERAPEUTICS LIMITED's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

View Full Report:
http://www.acutemarketreports.com/report/karus-therapeutics-limited-product-pipeline-review-2015

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.


Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of KARUS THERAPEUTICS LIMITED including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of KARUS THERAPEUTICS LIMITED's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the KARUS THERAPEUTICS LIMITED's pipeline products


Reasons to buy

- Evaluate KARUS THERAPEUTICS LIMITED's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of KARUS THERAPEUTICS LIMITED in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the KARUS THERAPEUTICS LIMITED's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of KARUS THERAPEUTICS LIMITED and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of KARUS THERAPEUTICS LIMITED
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of KARUS THERAPEUTICS LIMITED and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

About Us:
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends. Our database consists of 200,000+ market research reports with detailed & minute market research.
Acute Market Reports
Office No 101, 1st Floor,
Aditi Mall, Baner,
Pune, MH, 411045
India
Toll Free(US/CANADA): +1-855-455-8662
Website: http://www.acutemarketreports.com/

Tuesday, 5 January 2016

BioArctic Neuroscience AB - Product Pipeline Review Market Edition and Outlook Report 2015 - Acute Market Reports

'AFFIBODY AB - Product Pipeline Review - 2015', provides an overview of the AFFIBODY AB's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AFFIBODY AB's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

View Full Report: http://www.acutemarketreports.com/report/affibody-ab-product-pipeline-review-2015

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.


Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of AFFIBODY AB including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of AFFIBODY AB's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the AFFIBODY AB's pipeline products


Reasons to buy

- Evaluate AFFIBODY AB's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of AFFIBODY AB in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the AFFIBODY AB's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of AFFIBODY AB and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of AFFIBODY AB
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of AFFIBODY AB and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

About Us:
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends. Our database consists of 200,000+ market research reports with detailed & minute market research.
Acute Market Reports
Office No 101, 1st Floor,
Aditi Mall, Baner,
Pune, MH, 411045
India
Toll Free(US/CANADA): +1-855-455-8662
Website: http://www.acutemarketreports.com/